Statin-associated memory loss: Analysis of 60 case reports and review of the literature

Pharmacotherapy

Volumn 23, Issue 7, 2003, Pages 871-880

  Wagstaff, Leslie R ^a   Mitton, Melinda W ^a   Arvik, Beth McLendon ^a   Doraiswamy, P Murali ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ANTICOAGULANT AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; MEVINOLIN; NON PRESCRIPTION DRUG; PLACEBO; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; STEROID; THYROID HORMONE;

AMNESIA; CEREBROSPINAL FLUID; CHOLESTEROL INTAKE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISABILITY; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK FACTOR;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MEMORY DISORDERS; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; SIMVASTATIN;

EID: 0038381775     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.7.871.32720     Document Type: Review

References (27)

1. Sparks DL, Connor DJ, Browne PJ, et al. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advised to use one that crosses the bloodbrain barrier. J Nutr Health Aging 2002;6:324-31.
2. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
3. Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G. Decrease prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
4. Rockwood K, Kirkland S, Hogan D, at al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7.
5. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, stalin use, and cognitive function in older women. Arch Neurol 2002;59:378-84.
6. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol 2002;57:M414-18.
7. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001;21:767-9.
8. King DS, Jones DW, Wofford MR, Harkins K, Harrell TK, Kelley KNV. Cognitive impairment associated with atorvastatin [abstr]. Pharmacotherapy 2001;21:371.
9. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
10. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
11. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000;108:538-46.
12. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolemia. Br J Clin Pharmacol 1995;39:333-6.
13. Harrison RWS, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994;37:231-6.
14. Simons M, Schwärzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346-50.
15. Wardle J, Rogers P, Judd P, et al. Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. Am J Med 2000;108:547-53.
16. Prince MJ, Macdonald AM, Sham PC, et al. The development and initial validation of a telephone-administered cognitive test battery (TACT). Int J Methods Psych Res 1999;8:49-57.
17. Larosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. JAMA 1999;282(24):2340-6.
18. Serajuddin AT, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure-pharmacological considerations of HMG-Co A reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 1991;80:830-4.
19. Wolozin B, Siegal G. Report on statins and dementia disputed [reply]. Arch Neurol 2001;58:1167.
20. Birkenhäger WH, Wang JG, Staessen JA. Dementia and statins [letter]. Lancet 2001;357:880.
21. Bristol-Myers Squibb Pharmaceutical. Pravachol (pravastatin) package insert. Princeton, NJ; 2002.
22. Merck & Co., Inc. Zocor (simvastatin) package insert, Whitehouse Station, NJ; 2002.
23. Pfizer, Inc. Lipitor (atorvastatin) package insert, New York, NY; 2002.
24. Pfizer, Inc. Data on file. New York, NY; 2002.
25. Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci 2001;187:81-9.
26. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001;98:5856-61.
27. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 2002;16:131-6.